Citations 1
A phase I study of BAY 43–9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)
Adjei, Alex A. , Mandrekar, Sumithra J. , Marks, Randolph S., Hanson, L., Aranguren, Dawn, Jett, James R., Simantov, Ronit, Croghan, Gary A., Schwartz, Brian E.
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3067-3067
